Zilucoplan

Therapeutic

Zilucoplan is a complement inhibitor used to treat generalised myasthenia gravis in anti-acetylcholine receptor antibody-postive adults

Structural features

SMILES

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](C1CCCCC1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CNC5=C4C=CC=N5)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(=O)O)N(C)C(=O)[C@@H]7CC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O

Sequence

Ac-KVERFDXXYXEYPXKXgX

Molar mass

3562.23 g/mol

Constitutional members:

18

Natural amino acids

12

D-Amino acids

0

N-terminus

acetyl

C-terminus

OH

Cyclic

yes

Members/cycle

6

Bond to form cycle

head-to-tail

Lipidation

yes

Glycosylation

no

Route of administration

SC

Terminal half-life

172 hours

Protein binding

>99%

Absorption and Bioavailability

Peak plasma concentration ranges between 3 to 6 hours from 0.3 mg/kg dose via subcutaneous administration. Daily administration provides a steady state of concentration by 4 weeks of treatment. Less than 1% is execreted from urine and feces.

References